The Korean Journal of Pain

  • 제37권3호
  • /
  • Pages.247-255
  • /
  • 2024
  • /
  • 2005-9159(pISSN)
  • /
  • 2093-0569(eISSN)
대한통증학회 (The Korean Pain Society)
권호 표지
DOI QR코드

DOI QR Code

Persistent headache and chronic daily headache after COVID-19: a prospective cohort study

  • Larissa Clementino Leite Sa Carvalho (Hospital Universitario Oswaldo Cruz, Universidade de Pernambuco (UPE)) ;
  • Priscila Aparecida da Silva (Scientific Initiation Fellowships Institutional Program (CNPq/PROPESQI-UFPE), Centro de Ciências Médicas, Universidade Federal de Pernambuco (UFPE)) ;
  • Pedro Augusto Sampaio Rocha-Filho (Hospital Universitario Oswaldo Cruz, Universidade de Pernambuco (UPE))
  • 투고 : 2024.02.13
  • 심사 : 2024.04.05
  • 발행 : 2024.07.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Little is known about the frequency and impact of the persistent headache and about the incidence of chronic daily headache (CDH) after coronavirus disease 2019 (COVID-19). The aim of this prospective cohort study was to assess the incidence, risk factors, characteristics, and impact of CDH in patients with COVID-19. Methods: In the first stage, 288 patients were interviewed by telephone after the acute phase of COVID-19. Subsequently, 199 patients who presented headache were reinterviewed at least one year after COVID-19. Headaches that persisted beyond the acute phase of COVID-19 for three or more months and presented frequency ≥ 45 days over the first three months were considered to be CDH. Results: One hundred and twenty-three patients were included, 56% were females; median age: 50 years (25th and 75th percentile: 41;58). The headache persisted beyond the acute phase of COVID-19 in 52%, and 20.3% had CDH (95% confidence interval: 13.6-28.2). Individuals who previously had headaches and who had headaches of greater intensity during the acute phase were at higher risk of developing CDH. The group with CDH included more females, greater impact of headache, more persistence of headache beyond the 120th day of COVID-19 and less throbbing headache than did the other individuals whose headache persisted. Conclusions: Patients who had COVID-19 had a high incidence of CDH. Previous headache and greater intensity of headache were associated with higher risk of CDH.

키워드

참고문헌

  1. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144.
  2. Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of postCOVID-19 syndrome: a meta-analysis. J Neurol Sci 2022; 434: 120162.
  3. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al. Attributes and predictors of long COVID. Nat Med 2021; 27: 626-31. Erratum in: Nat Med 2021; 27: 1116.
  4. Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 2021; 4: e2111417.
  5. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of postcoronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022; 226: 1593-607.
  6. Venkatesan P. NICE guideline on long COVID. Lancet Respir Med 2021; 9: 129.
  7. Shanthanna H, Nelson AM, Kissoon N, Narouze S. The COVID-19 pandemic and its consequences for chronic pain: a narrative review. Anaesthesia 2022; 77: 1039-50.
  8. Kim N, Kim J, Yang BR, Hahm BJ. Associations of unspecified pain, idiopathic pain and COVID-19 in South Korea: a nationwide cohort study. Korean J Pain 2022; 35: 458-67.
  9. Sampaio Rocha-Filho PA. Headache associated with COVID-19: epidemiology, characteristics, pathophysiology, and management. Headache 2022; 62: 650-6.
  10. Rocha-Filho PAS, Magalhaes JE. Headache associated with COVID-19: frequency, characteristics and association with anosmia and ageusia. Cephalalgia 2020; 40: 1443-51.
  11. Sampaio Rocha-Filho PA, Magalhaes JE, Fernandes Silva D, Carvalho Soares M, Marenga Arruda Buarque L, Dandara Pereira Gama M, et al. Neurological manifestations as prognostic factors in COVID-19: a retrospective cohort study. Acta Neurol Belg 2022; 122: 725-33.
  12. Fernandez-de-Las-Penas C, Navarro-Santana M, Gomez-Mayordomo V, Cuadrado ML, Garcia-Azorin D, Arendt-Nielsen L, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol 2021; 28: 3820-5.
  13. Fernandez-de-Las-Penas C, Cuadrado ML, GomezMayordomo V, Torres-Macho J, Pellicer-Valero OJ, Martin-Guerrero JD, et al. Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants. Headache 2022; 62: 1148-52.
  14. Nersesjan V, Amiri M, Lebech AM, Roed C, Mens H, Russell L, et al. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up. J Neurol 2021; 268: 3086-104.
  15. Akinci T. Post-discharge persistent headache and smell or taste dysfunction after hospitalisation for COVID-19: a single-centre study. Ir J Med Sci 2023; 192: 369-75.
  16. Ali M. Severe acute respiratory syndrome coronavirus 2 infection altered the factors associated with headache: evidence from a multicenter communitybased case-control study. Pain Rep 2022; 7: e1051.
  17. Collantes MEV, Espiritu AI, Sy MCC, Anlacan VMM, Jamora RDG. Neurological manifestations in COVID-19 infection: a systematic review and metaanalysis. Can J Neurol Sci 2021; 48: 66-76.
  18. Rodriguez-Perez MP, Sanchez-Herrera-Baeza P, Rodriguez-Ledo P, Serrada-Tejeda S, Garcia-Bravo C, Perez-de-Heredia-Torres M. Headaches and dizziness as disabling, persistent symptoms in patients with long COVID-A national multicentre study. J Clin Med 2022; 11: 5904.
  19. Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla JA, Caronna E, Gonzalez-Martinez A, et al. Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients. Cephalalgia 2022; 42: 804-9.
  20. Sampaio Rocha-Filho PA, Albuquerque PM, Carvalho LCLS, Dandara Pereira Gama M, Magalhaes JE. Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study. J Headache Pain 2022; 23: 2.
  21. Mattos ACMT, Souza JA, Moreira PF Filho, Jurno ME, Velarde LGC. ID-MigraineTM questionnaire and accurate diagnosis of migraine. Arq Neuropsiquiatr 2017; 75: 446-50.
  22. Martin M, Blaisdell B, Kwong JW, Bjorner JB. The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol 2004; 57: 1271-8.
  23. Caronna E, Ballve A, Llaurado A, Gallardo VJ, Ariton DM, Lallana S, et al. Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia 2020; 40: 1410-21.
  24. Sampaio Rocha-Filho PA. Headache associated with coronavirus disease 2019. Neurol Clin 2024; 42: 507-20.
  25. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1-211.
  26. Sousa Melo E, Pedrosa RP, Carrilho Aguiar F, Valente LM, Sampaio Rocha-Filho PA. Dialysis headache: characteristics, impact and cerebrovascular evaluation. Arq Neuropsiquiatr 2022; 80: 129-36.
  27. Oliveira FAA, Sampaio Rocha-Filho PA. Headaches attributed to ischemic stroke and transient ischemic attack. Headache 2019; 59: 469-76.
  28. Rocha-Filho PA. Post-craniotomy headache: a clinical view with a focus on the persistent form. Headache 2015; 55: 733-8.
  29. Rocha-Filho PA, Gherpelli JL, de Siqueira JT, Rabello GD. Post-craniotomy headache: characteristics, behaviour and effect on quality of life in patients operated for treatment of supratentorial intracranial aneurysms. Cephalalgia 2008; 28: 41-8.
  30. Rocha-Filho PA, Gherpelli JL, de Siqueira JT, Rabello GD. Post-craniotomy headache: a proposed revision of IHS diagnostic criteria. Cephalalgia 2010; 30: 560-6.
  31. Moskatel LS, Smirnoff L. Protracted headache after COVID-19: a case series of 31 patients from a tertiary headache center. Headache 2022; 62: 903-7.
  32. Planchuelo-Gomez A, Garcia-Azorin D, Guerrero AL, Rodriguez M, Aja-Fernandez S, de Luis-Garcia R. Structural brain changes in patients with persistent headache after COVID-19 resolution. J Neurol 2023; 270: 13-31.
  33. Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain 2019; 20: 80.
  34. Peng KP, Wang SJ. Update of new daily persistent headache. Curr Pain Headache Rep 2022; 26: 79-84.
  35. Simmons AC, Bonner A, Giel A, Pezzano A, Rothner AD. Probable new daily persistent headache after COVID-19 in children and adolescents. Pediatr Neurol 2022; 132: 1-3.
  36. Sampaio Rocha-Filho PA, Voss L. Persistent headache and persistent anosmia associated with COVID-19. Headache 2020; 60: 1797-9.
  37. Dono F, Consoli S, Evangelista G, D'Apolito M, Russo M, Carrarini C, et al. New daily persistent headache after SARS-CoV-2 infection: a report of two cases. Neurol Sci 2021; 42: 3965-8.
  38. Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Toward a better understanding of persistent headache after mild COVID-19: three migraine-like yet distinct scenarios. Headache 2021; 61: 1277-80.
  39. Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia 2002; 22: 66-9.
  40. Prakash S, Saini S, Rana KR, Mahato P. Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India. J Headache Pain 2012; 13: 477-85.
  41. Evans RW. Primary non-continuous new daily persistent headache: seven cases and proposed diagnostic criteria. Cephalalgia Rep 2021; 4: 1-4.
  42. Fernandez-de-Las-Penas C, Gomez-Mayordomo V, Garcia-Azorin D, Palacios-Cena D, Florencio LL, Guerrero AL, et al. Previous history of migraine is associated with fatigue, but not headache, as longterm post-COVID symptom after severe acute respiratory SARS-CoV-2 infection: a case-control study. Front Hum Neurosci 2021; 15: 678472.
  43. Magdy R, Elmazny A, Soliman SH, Elsebaie EH, Ali SH, Abdel Fattah AM et al. Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case-control study. J Headache Pain 2022; 23: 101.
  44. Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 2018; 19: 50.